WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2010118986) FLUORO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK3 INHIBITORS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2010/118986    International Application No.:    PCT/EP2010/054685
Publication Date: 21.10.2010 International Filing Date: 09.04.2010
IPC:
C07D 403/12 (2006.01), C07D 239/48 (2006.01), C07D 407/12 (2006.01), A61K 31/506 (2006.01), A61K 31/5377 (2006.01), A61P 35/00 (2006.01)
Applicants: CELLZOME LIMITED [GB/GB]; Chesterford Research Park, Little Chesterford Cambridge CB10 1XL (GB) (For All Designated States Except US).
HARRISON, Richard John [GB/GB]; (GB) (For US Only).
HOBSON, Andrew [GB/GB]; (GB) (For US Only).
RAMSDEN, Nigel [GB/GB]; (GB) (For US Only)
Inventors: HARRISON, Richard John; (GB).
HOBSON, Andrew; (GB).
RAMSDEN, Nigel; (GB)
Agent: BÜCHEL, Edwin; Isenbruck Bösl Hörschler LLP Patentanwälte Eastsite One Seckenenheimer Landstraße 4 68163 Mannheim (DE)
Priority Data:
09157844.3 14.04.2009 EP
61/241,476 11.09.2009 US
Title (EN) FLUORO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK3 INHIBITORS
(FR) COMPOSÉS DE PYRIMIDINE SUBSTITUÉS PAR FLUORO EN TANT QU'INHIBITEURS DE JAK3
Abstract: front page image
(EN)The present invention relates to compounds of formula (I) wherein AA, R2 to R7 and X1 to X3 have the meaning as cited in the description and the claims. Said compounds are useful as selective inhibitors of JAK3 over JAK2 for the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders, and immunologically-mediated diseases. The invention also relates to pharmaceutical compositions including said compounds, the preparation of such compounds as well as the use as medicaments.
(FR)La présente invention porte sur des composés représentés par la formule (I) : dans laquelle AA, R2 à R7 et X1 à X3 présentent la signification telle qu'indiquée dans la description et les revendications. Lesdits composés sont utiles en tant qu'inhibiteurs sélectifs de JAK3 par rapport à JAK2 pour le traitement ou la prévention de troubles immunologiques, inflammatoires, auto-immuns, allergiques et de maladies à médiation immunologique. L'invention porte également sur des compositions pharmaceutiques renfermant lesdits composés, sur la préparation de tels composés, ainsi que sur leur utilisation en tant que médicaments.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)